Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Epithelial Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm

Cancer Family

Epithelial Neoplasm

CI-CAN-00000016Explore in graph →

Non-malignant7,525 active trials118 approved drugs1,152 evidence items

NCIt: C3709

Overview
Statistics
Survival
Genomics314
Variants & evidence1152
Drugs206
Trials26878
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (916)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 26–50 of 916 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
· N Engl J Med · 2024 · PMID 38598794 · validated civic_curation pubmed
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
· N Engl J Med · 2023 · PMID 37937763 · validated civic_curation pubmed
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
· N Engl J Med · 2023 · PMID 37870969 · validated civic_curation pubmed
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
· N Engl J Med · 2014 · PMID 25264305 · validated civic_curation pubmed
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
· Lancet Oncol · 2016 · PMID 26874901 · validated civic_curation pubmed
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
· N Engl J Med · 2005 · PMID 16236737 · validated civic_curation pubmed
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
· Lancet · 2010 · PMID 20728210 · validated civic_curation pubmed

Showing 26–50 of 916 publications

← Previous
1
2
3
…
37
Next →

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

· Lancet Oncol · 2016 · PMID 27283860 · validated civic_curation pubmed

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.

· N Engl J Med · 2019 · PMID 31340094 · validated civic_curation pubmed

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.

· J Clin Oncol · 2018 · PMID 29596029 · validated civic_curation pubmed

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

· Lancet Oncol · 2020 · PMID 32203698 · validated civic_curation pubmed

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.

· N Engl J Med · 2020 · PMID 32877583 · validated civic_curation pubmed

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.

· N Engl J Med · 2020 · PMID 32846061 · validated civic_curation pubmed

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.

· J Clin Oncol · 2021 · PMID 34339292 · validated civic_curation pubmed

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.

· JAMA Oncol · 2021 · PMID 34647988 · validated civic_curation pubmed

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.

· Lancet Gastroenterol Hepatol · 2021 · PMID 34358484 · validated civic_curation pubmed

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.

· Lancet Oncol · 2021 · PMID 34118197 · validated civic_curation pubmed

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

· Br J Cancer · 2014 · PMID 24263064 · validated civic_curation pubmed

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

· N Engl J Med · 2016 · PMID 27717299 · validated civic_curation pubmed

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.

· J Clin Oncol · 2023 · PMID 37694347 · validated civic_curation pubmed

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.

· N Engl J Med · 2023 · PMID 37870976 · validated civic_curation pubmed

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.

· Ann Oncol · 2024 · PMID 38942080 · validated civic_curation pubmed

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.

· Ann Oncol · 2024 · PMID 37879444 · validated civic_curation pubmed

Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.

· N Engl J Med · 2025 · PMID 39908431 · validated civic_curation pubmed

Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study.

· J Clin Oncol · 2025 · PMID 39761483 · validated civic_curation pubmed